Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Vaccine efficacy

Pneumococcal vaccine reduces antibiotic resistant infections in children by 62%

Researchers examined the incidence of antibiotic-resistant invasive pneumococcal disease in children after the 13-valent pneumococcal conjugate vaccine was introduced in the United States.

13-valent pneumococcal conjugate vaccine (PCV13) reduces the incidence of antibiotic resistant pneumococcal infections in children under five years by 62%, says study

Source: ChameleonsEye / Shutterstock.com

The 13-valent pneumococcal conjugate vaccine replaced the 7-valent pneumococcal conjugate vaccine for immunisation of children in the United States in 2010

The 13-valent pneumococcal conjugate vaccine (PCV13) reduced the incidence of antibiotic resistant pneumococcal infections in children aged under five years by 62% between 2009 and 2013, according to a US study presented at the annual meeting of the Infectious Diseases Society of America (IDSA) on 10 October 2014.

Pneumococcal infection is the most common cause of death preventable by a vaccine and can cause a variety of problems, including ear infections, pneumonia and meningitis.

The PCV13 replaced the 7-valent pneumococcal conjugate vaccine (PCV7) for immunisation of children in the United States in 2010. Researchers at the US Centers for Disease Control and Prevention (CDC) looked at data representing approximately 10% of the US population to examine the incidence of antibiotic-resistant invasive pneumococcal disease in children after the PCV13 vaccine was initiated.

“We’re at risk of living in a post-antibiotic world, where these miracle medications no longer work, but this vaccine is part of the solution to protecting ourselves from the growing threat of antibiotic resistance,” said lead researcher Sara Tomczyk, epidemic intelligence service officer for the Respiratory Diseases Branch at CDC in Atlanta. “Not only does this vaccine prevent pneumococcal infection, which means fewer antibiotics are prescribed, but it also prevents antibiotic-resistant infections.”

The US government’s Healthy People 2020 had set a goal of reducing antimicrobial-resistant invasive pneumococcal disease to 6 cases per 100,000 children. The CDC researchers found that the rate is now 3.5 cases per 100,000 children, meaning that the goal has been met early.

A 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the UK routine childhood immunisation programme in 2006 and was replaced by a 13-valent pneumococcal conjugate vaccine (PCV13) in April 2010.

 

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066782

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.